Gemina Laboratories Ltd. (GLAB) AI Stock Analysis

• Market Cap: C$3.06M
• Dividend Yield: N/A
• Average Volume (3M): 13.56K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.80
• Revenue Growth: N/A
• EPS Growth: 9.06%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 76,570,910
• 10 Day Avg. Volume: 19,305
• 30 Day Avg. Volume: 13,558
• PEG Ratio: 0.42
• Price to Book (P/B): -9.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -30.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.04 ▼(-36.67% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is driven primarily by weak financial performance (minimal revenue, large losses, and negative equity), which signals elevated execution and financing risk. Technicals also weigh heavily, with the price below all key moving averages and negative MACD indicating a persistent downtrend. Valuation provides limited support because the company is loss-making (negative P/E) and has no stated dividend yield.

Positive Factors

Improved cash generation

A move from persistent cash burn to slight positive operating and free cash flow reflects operational improvement versus prior years. If sustained, even modest positive cash generation reduces near-term financing urgency and extends runway, improving strategic flexibility for R&D or commercialization steps.

Modest absolute debt load

Low nominal debt limits fixed interest obligations and reduces near-term default risk relative to heavily leveraged peers. This weaker leverage footprint preserves optionality for funding via debt or equity and gives management more capacity to prioritize R&D or product development without large mandatory cash outflows.

Shrinking reported losses

A reduction in the trailing loss versus prior annual results signals progress toward cost control or transitional revenue recognition. For an early-stage biotech, shrinking losses improve runway visibility, reduce frequency/size of financing needs, and can increase investor willingness to support next development milestones.

Negative Factors

Minimal recurring revenue

The company lacks meaningful product or service revenue and reports negative gross profit, which undermines proof of commercial traction. Without scalable revenue, the business must rely on financing for operations, making durable margin improvement and self-funded growth unlikely absent material commercial progress.

Negative shareholder equity

An accumulated deficit that produces negative equity signals long-standing losses have exhausted capital reserves. This constrains strategic options, increases insolvency and covenant risks, and raises the probability of dilutive financings or balance-sheet restructuring to restore solvency and fund ongoing R&D.

Fragile cash-flow improvement

The positive operating/free cash flow figures are tiny relative to the multi-million net loss, so cash-generation gains may not be durable. Continued R&D and operating needs likely require fresh capital, leaving the company exposed to execution risk, dilution pressure, and potential interruptions if funding windows close.

Gemina Laboratories Ltd. Business Overview & Revenue Model

Company Description

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

Gemina Laboratories Ltd. generates revenue primarily through the sale of its diagnostic products to healthcare providers, laboratories, and other medical institutions. The company may also engage in partnerships and collaborations with other biotechnology firms and research institutions to enhance the development and distribution of its products. Licensing its proprietary technology to other companies for use in their diagnostic solutions could serve as an additional revenue stream. Furthermore, Gemina might receive funding or grants from governmental or non-governmental organizations interested in promoting advanced healthcare solutions.

Gemina Laboratories Ltd. Financial Statement Overview

Summary

Very weak fundamentals: TTM revenue is extremely small (~10.9K) with deeply negative profitability (net loss ~2.93M) and negative gross profit. Balance sheet risk is high with persistent negative shareholder equity (TTM ~-5.14M). Cash flow has improved to slightly positive TTM operating/FCF (~0.6K), but the magnitude is too small to offset ongoing losses and financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (about 10.9K) and profitability is deeply negative, with a negative gross profit and a large net loss (~2.93M). The business has not demonstrated a consistent ability to generate product revenue in the annual periods shown (revenue reported as 0 across 2021–2025 annual reports), and losses remain substantial even though the TTM loss is smaller than the prior annual loss. Overall, the income profile reflects an early-stage biotech still far from operating leverage.

Balance Sheet

The balance sheet shows persistent negative shareholder equity (TTM equity around -5.14M), which is a meaningful financial risk signal and limits flexibility. Total debt in TTM is relatively modest (~240K) versus total assets (~1.11M), but the negative equity base indicates accumulated losses have overwhelmed capital. Compared with earlier years, leverage appears lower in absolute terms, yet the capital structure remains strained due to the deficit position.

Cash Flow

Cash flow is the relative bright spot: TTM operating cash flow and free cash flow are slightly positive (~0.6K each), a notable improvement from multiple years of heavy cash burn (annual operating cash flow was materially negative from 2021 through 2025). However, the improvement looks fragile given the very small positive amounts and the still-large net loss in TTM, indicating cash generation is not yet supported by sustainable operations.

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Jan 2021
Income Statement
Total Revenue	10.88K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-23.89K	-113.24K	-93.37K	-50.28K	-43.83K	-12.09K
EBITDA	-2.78M	-3.80M	-5.18M	-5.93M	-4.69M	-819.60K
Net Income	-2.93M	-4.07M	-5.22M	-5.98M	-4.74M	-834.15K
Balance Sheet
Total Assets	1.11M	1.44M	1.46M	1.87M	1.42M	2.53M
Cash, Cash Equivalents and Short-Term Investments	-613.00	703.00	990.00	83.09K	1.17M	898.05K
Total Debt	240.11K	1.27M	485.33K	240.84K	46.08K	98.13K
Total Liabilities	6.25M	5.87M	3.04M	1.95M	475.92K	2.37M
Stockholders Equity	-5.14M	-4.44M	-1.59M	-71.81K	944.23K	159.96K
Cash Flow
Free Cash Flow	586.00	-1.30M	-3.29M	-4.59M	-3.88M	-319.09K
Operating Cash Flow	582.00	-1.30M	-3.24M	-4.51M	-3.87M	-319.09K
Investing Cash Flow	18.42K	18.42K	-41.35K	-505.07K	8.20K	13.91K
Financing Cash Flow	-61.22K	1.28M	3.20M	3.94M	4.14M	2.72M

Gemina Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLAB, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.06, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 32.20 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLAB.

Gemina Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-3.36	-107.76%	―	―	34.22%
MOOD	47 Neutral	C$4.33M	-4.14	-41.36%	―	-50.89%	-32.33%
HEAL	44 Neutral	C$3.84M	-2.46	―	―	―	―
GLAB	41 Neutral	C$3.06M	-1.03	―	―	―	9.06%

Gemina Laboratories Ltd. Corporate Events

Gemina Laboratories Plans Secured Debenture Financing and Voluntary CSE Delisting

Gemina Laboratories Ltd. plans to raise between $1 million and $3 million through a non-brokered private placement of secured, non-convertible debentures, each with a $1,000 face value, a 12-month term and an 18% annual interest rate, secured by a first-priority charge over the company’s intellectual property. The debentures will give majority holders substantial governance rights, including the ability to appoint at least half of the board and approve any new material liabilities, and proceeds are earmarked to repay specific secured debt, including a shareholder loan, and to bolster general working capital. The offering, which may close in tranches by mid-January 2026, is contingent on using proceeds to fully discharge existing secured debt and remains subject to regulatory approvals and execution of definitive agreements, with no certainty it will be completed as proposed. In tandem, Gemina intends to voluntarily delist its common shares from the CSE, pending exchange and disinterested shareholder approval expected at a meeting in February 2026, arguing that leaving the public market in the face of prolonged weak conditions will cut listing-related costs, preserve capital and provide greater flexibility in securing funding, a move that could significantly reshape its capital structure and governance while reducing public-market liquidity for existing shareholders.